TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03069118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment - Workit Health Online Program
Description: The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control - Resource List
Description: Tailored list of resources.
Study: NCT03729973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients nebulized ketamine by compressor nebulizing for 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes.
Study: NCT00817583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, fluorouracil
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
Study: NCT03181373

Intervention type: OTHER
Intervention: Cognitive rehabilitation program
Description: Rehabilitation
Study: NCT02854410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
Study: NCT04588558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy group
Description: The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises
Study: NCT01796470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Entospletinib tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally twice daily
Study: NCT02854410

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
Study: NCT06409403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clinical application of robotic technique
Description: effect of various surgical technique on clinical efficacy of TME
Study: NCT01367782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
Study: NCT02393560

Intervention type: PROCEDURE
Intervention: DECT scan
Study: NCT03371524

Intervention type: OTHER
Intervention: Cardiac Echography
Description: While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
Study: NCT02633527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg SPN-812
Description: 100mg SPN-812 was administered once daily and compared to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study: NCT02633527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg SPN-812
Description: 300mg SPN-812 was administered once daily and compared to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT00831155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches, Denicotinized Cigarettes
Description: Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
Study: NCT04591587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery
Description: Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
Study: NCT04044794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Self-Weighing
Description: Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
Study: NCT03329209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.
Study: NCT02004691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olipudase alfa
Description: Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion
Study: NCT01256697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil
Description: 9-cis Rich Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawill
Description: 9-cis Rich Powder
Study: NCT03093363

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist's intervention
Description: Pharmacist's intervention with asthmatic patients:~* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~* Explanation of asthma and inflammation~* Explanation of triggers and how to avoid it~* Explanation of asthma treatments~* Explanation of the inhalation technique with a physical demonstration~* Emphasis on treatment adherence~* Assessment of comorbidities and their treatment~* Emphasis on influenza vaccination

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires for control group
Description: - Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
Study: NCT00884819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: fenofibrate 200 mg daily for 6-months
Study: NCT01256697

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill
Study: NCT01068704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-690514
Description: Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
Study: NCT00884819

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match for 6 months
Study: NCT02810808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1+PRN
Description: PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3+PRN
Description: PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
Study: NCT01481935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced cleaning of surfaces in ICU rooms
Description: Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham enhanced cleaning of surfaces in ICU rooms
Description: While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
Study: NCT01988987

Intervention type: OTHER
Intervention: Inpatient Postpartum GTT
Description: Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
Study: NCT01068704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
Study: NCT04548232

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: bariatric surgery
Study: NCT05708898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal exerciser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham pharyngeal exerciser
Study: NCT00671463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting
Description: In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
Study: NCT02636881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Chondrocyte Implantation
Description: Implantation of the patients own cartilage cells in a chondral defect of the knee

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopic Debridement
Description: Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
Study: NCT03194061

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: 20 fractions of 275cGy 5 days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin
Description: Concomitant weekly cisplatin 35mg/m2 x 4 weeks
Study: NCT01939938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal and Oronasal PAP Mask
Description: Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
Study: NCT01661881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT03557255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
Study: NCT02963597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSense™ 10 AutoSet
Description: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard medical therapy according to current guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard medical therapy according to current guidelines.
Study: NCT04488874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol 20% Infusion
Description: Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
Study: NCT03212365

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed dose
Description: Participants will receive 40 mg enoxaparin twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variable dose
Description: Participants will receive 0.5mg/kg enoxaparin twice daily
Study: NCT00005982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00165152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Informed Consent Counseling
Description: Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
Study: NCT03050294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls twice daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily
Study: NCT06409403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clinical application of robotic technique
Description: effect of various surgical technique on clinical efficacy of TME
Study: NCT03462069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03050294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone 0.25% spray applied twice daily
Study: NCT02721199

Intervention type: OTHER
Intervention: Neural Respiratory Drive Automated EMGpara assessment
Description: Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
Study: NCT03462069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00478374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg bid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation with doxorubicin
Description: Transarterial chemoembolisation (TACE)
Study: NCT04186481

Intervention type: DEVICE
Intervention: MINITAC Ti 2.0 suture anchor
Description: The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
Study: NCT04658173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam-alfentanil combination
Description: Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-alfentanil combination
Description: Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
Study: NCT01231230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: 220- mcg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo inhalation
Description: placebo inhalation once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 mcg salmeterol once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol
Description: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol